Company news
Zenas Biopharma, Inc. (NASDAQ:ZBIO) news
Zenas Biopharma, Inc. news releases on 6ix. Latest, Oct 6, 2026: Zenas BioPharma to Host Virtual R&D Event
Press releases & updates
Zenas BioPharma to Host Virtual R&D Event
October 6, 2026
Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026
September 22, 2026
Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event
September 8, 2026
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 13, 2026
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine
June 2, 2026
Zenas BioPharma Announces Submission of Biologics License Application to U.S. FDA for Obexelimab in IgG4-RD
May 29, 2026
Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD
May 28, 2026
Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress
May 19, 2026
Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
May 13, 2026
Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million
March 27, 2026
Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock
March 26, 2026
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 16, 2026
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
February 9, 2026
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
February 4, 2026
Zenas BioPharma Announces Inducement Grant under Nasdaq Listing Rule 5635(4)
January 19, 2026
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026
Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease
January 6, 2026
Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
January 5, 2026
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 19, 2025
Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
December 15, 2025
Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 12, 2025
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
November 11, 2025
Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
October 27, 2025
Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
October 8, 2025
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million
September 2, 2025
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
September 2, 2025
Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
August 12, 2025
Zenas BioPharma to Present at the Jefferies Global Healthcare Conference
May 29, 2025
Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates
May 15, 2025
Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer
April 7, 2025
Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer
March 17, 2025